683 Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

683 Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,400,000	Closed	-$7.99M	–	143
2025 Q1	$7.99M	Buy	2,400,000 +983,986	+69%	+$5.07M	0.55%	52
2024 Q4	$10.5M	Buy	1,416,014 +16,014	+1%	+$148K	0.65%	39
2024 Q3	$13.1M	Sell	1,400,000 -100,000	-7%	-$947K	1%	29
2024 Q2	$12M	Buy	1,500,000 +275,000	+22%	+$2.95M	0.91%	35
2024 Q1	$18.2M	Sell	1,225,000 -525,000	-30%	-$6.11M	1.33%	22
2023 Q4	$14.2M	Sell	1,750,000 -300,000	-15%	-$1.57M	1.17%	31
2023 Q3	$9.33M	Buy	2,050,000 +650,000	+46%	+$4.24M	0.73%	47
2023 Q2	$9.86M	Buy	1,400,000 +75,000	+6%	+$537K	0.71%	39
2023 Q1	$8.1M	Buy	1,325,000 +325,000	+33%	+$2.24M	0.6%	51
2022 Q4	$6.39M	Sell	1,000,000 -705,000	-41%	-$5.5M	0.54%	52
2022 Q3	$16.3M	Sell	1,705,000 -295,000	-15%	-$3.4M	1.26%	28
2022 Q2	$22.1M	Buy	2,000,000 +500,000	+33%	+$6.55M	1.56%	17
2022 Q1	$25M	Buy	1,500,000 +780,000	+108%	+$12.1M	1.34%	17
2021 Q4	$13.7M	Sell	720,000 -229,829	-24%	-$5.06M	0.51%	46
2021 Q3	$23.4M	Sell	949,829 -75,000	-7%	-$1.77M	0.91%	28
2021 Q2	$26.7M	Buy	+1,024,829	New	+$26.6M	0.92%	27
2021 Q1	–	Sell	-100,000	Closed	-$4.64M	–	206
2020 Q4	$4.64M	Hold	100,000	–	–	0.22%	70
2020 Q3	$3.29M	Hold	100,000	–	–	0.24%	70
2020 Q2	$2.75M	Hold	100,000	–	–	0.22%	69
2020 Q1	$2.99M	Buy	+100,000	New	+$2.65M	0.35%	58
2018 Q3	–	Sell	-350,000	Closed	-$4.48M	–	170
2018 Q2	$4.48M	Hold	350,000	–	–	0.3%	59
2018 Q1	$5.92M	Buy	350,000 +50,000	+17%	+$757K	0.52%	50
2017 Q4	$2.4M	Hold	300,000	–	–	0.2%	83
2017 Q3	$2.33M	Buy	+300,000	New	+$1.9M	0.24%	74

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

683 Capital Management's IOVA Position: Q2 2025 in Review

683 Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 2,400,000 shares — an estimated $7.99M sold.

683 Capital Management first reported a position in IOVA in Q3 2017 and held it in 24 quarters. The position peaked at $26.7M in Q2 2021. 255 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

683 Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
683 Capital Management sold 2,400,000 Iovance Biotherapeutics shares in Q2 2025, an estimated $7.99M.
683 Capital Management first reported a position in Iovance Biotherapeutics in Q3 2017 and held it in 24 quarters.
683 Capital Management's Iovance Biotherapeutics position peaked at $26.7M in Q2 2021.
255 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on 683 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.